Gabapentin treatment in a female patient with panic disorder and adverse effects under carbamazepine during benzodiazepine withdrawal;Gabapentin bei einer patientin mit panikstörung und unverträglichkeit von carbamazepin während des benzodiazepinentzugs

Psychiatrische Praxis

Volumn 34, Issue 2, 2007, Pages 93-94

  Himmerich, Hubertus ^a   Nickel, Thomas ^a   Dalal, Mira A ^a   Müller, Marianne B ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; GABAPENTIN;

ARTICLE; CASE REPORT; DRUG DEPENDENCE; DRUG WITHDRAWAL; FEMALE; HUMAN; PANIC; SIDE EFFECT; WITHDRAWAL SYNDROME;

AGED; ALPRAZOLAM; AMINES; ANTIMANIC AGENTS; BENZODIAZEPINES; CARBAMAZEPINE; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GAMMA-AMINOBUTYRIC ACID; HEPATITIS, TOXIC; HUMANS; LIVER FUNCTION TESTS; PANIC DISORDER; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 33947147667     PISSN: 03034259     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-915276     Document Type: Article

References (11)

1. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. AWMF-Leitlinie Angsterkrankungen, AWMF Reg.-Nr. 028/010
2. American Psychiatric Association, Work Group on Panic Disorder. Practice guideline for the treatment of patients with panic disorder. Am J Psychiatry 1998; 155, Suppl 5: 1-34
3. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 2004; 65, Suppl 5: 7-12
4. Pande AC, Davidson JR, Jefferson JW et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19: 341-348
5. Chatterjee CR, Ringold AL. A case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin. J Clin Psychiatry 1999; 60: 617
6. Crockford D, White WD, Campbell B. Gabapentin use in benzodiazepine dependence and detoxification. Can J Psychiatry 2001; 46: 287
7. Goa KL Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993; 46: 409-427
8. Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, Shiovitz T. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20: 467-471
9. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62: 1022-1030
10. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005; 25: 151-158
11. Lauria-Horner BA, Pohl RB. Pregabalin: a new anxiolytic. Expert Opin Invest Drugs 2003; 12: 663-672